EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome

Yunyun Zhu, Qiuyue Yu, Yangyang Ma, Li Huang, Jianguang Ding, Xiuhua Gao, Lili Ma, Dike Zhang, Bin Zhang, Sen Wang, Wai Kit Chu, Guannan Su and 1 more

Investigative Ophthalmology & Visual Science · 2026

DOI: 10.1167/iovs.67.6.4 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Yunyun Zhu and 12 co-authors. Institution: Department of Ophthalmology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China. Major MEDLINE topics: Uveomeningoencephalitic Syndrome, Adalimumab, Macrophages, Th1 Cells. Cited 2 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Purpose

To investigate the effects and underlying mechanisms of adalimumab on monocyte-derived macrophage polarization and CD4+ T cell responses in patients with Behçet's uveitis (BU) or Vogt-Koyanagi-Harada (VKH) syndrome.

Methods

Ex vivo analyses were performed on monocyte-derived macrophages and CD4+ T cells from patients with active BU (n = 43) and VKH (n = 35). In vivo experiments were performed using an experimental autoimmune uveitis (EAU) model. The effects of adalimumab on macrophage polarization and cytokine production were assessed using flow cytometry and enzyme-linked immunosorbent assay, respectively. The underlying adalimumab-induced immunomodulatory cascade was evaluated using coculture systems with healthy donor CD4⁺ T cells. Disease-specific mechanisms were investigated through integrated transcriptomic and proteomic profiling and validated by real-time quantitative polymerase chain reaction and western blot.

Results

Proinflammatory M1 macrophage polarization was significantly enhanced in patients with BU and VKH. Adalimumab selectively suppressed M1 polarization and the production of tumor necrosis factor-alpha, IL-1β, IL-6, and IL-12. These adalimumab-reprogrammed M1 macrophages promoted CD4+ T cell apoptosis and inhibited Th1/Th17 responses. However, adalimumab did not directly affect T cells. Multi-omics analysis and validation experiments revealed disease-specific mechanisms, notably the significant downregulation of the expression of metallothionein members, including MT1H, MT1G, MT1A, MT1F, MT1E, MT1X, and MT2A, in BU and that of SLC39A8 in VKH. Furthermore, adalimumab therapy reversed the increased frequencies of CD80+ macrophages and Th1/Th17 cells in the spleen and in association with remission of uveitis in the EAU model.

Conclusions

Adalimumab modulates macrophage polarization to attenuate T cell-mediated inflammation by targeting different proteins in BU and VKH, providing novel insights for precision immunotherapy in uveitis.

Subjects

MeSH terms (MEDLINE)

Uveomeningoencephalitic SyndromeAdalimumabMacrophagesTh1 CellsTh17 CellsBehcet SyndromeAnti-Inflammatory AgentsUveitisHumansAnimalsEnzyme-Linked Immunosorbent AssayFlow CytometryFemaleMaleCytokinesBlotting, WesternReal-Time Polymerase Chain ReactionCells, CulturedDisease Models, AnimalCD4-Positive T-LymphocytesAdult

Substances

AdalimumabCytokinesAnti-Inflammatory Agents

Authors and institutions

  • Department of Ophthalmology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
  • Postdoctoral Mobile Station of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Department of Ophthalmology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Department of Emergency, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
  • Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
  • Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.

Cite

APA

Zhu, Y., Yu, Q., Ma, Y., Huang, L., Ding, J., Gao, X., Ma, L., Zhang, D., Zhang, B., Wang, S., Chu, W. K., Su, G., & Yang, P. (2026). Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.6.4

Vancouver

Zhu Y, Yu Q, Ma Y, Huang L, Ding J, Gao X, et al. Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.6.4

BibTeX
@article{Zhu2026,
  author = {Zhu, Yunyun and Yu, Qiuyue and Ma, Yangyang and Huang, Li and Ding, Jianguang and Gao, Xiuhua and Ma, Lili and Zhang, Dike and Zhang, Bin and Wang, Sen and Chu, Wai Kit and Su, Guannan and Yang, Peizeng},
  title = {Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2026},
  doi = {10.1167/iovs.67.6.4}
}
Start for free →